2025-04-15 22:37:47
Latest Post
ICICI Lombard General Insurance Company Ltd Q4 FY2024-25 consolidated profit lower at Rs. 509.59 crores
Indian Renewable Energy Development Agency Ltd Q4 FY2025 consolidated PAT increases to Rs. 501.55 crores
IndiGo Swiftly and Successfully Shifts Operations from Terminal 2 to Terminal 1 at Indira Gandhi International Airport, Delhi
Oil India secures 9 blocks under OALP IX
Cairn Oil & Gas, Vedanta acquires 7 new blocks in OALP Round-IX
Stock Report
Vivimed Labs Ltd Q2 FY2023 consolidated loss at Rs. 22.03 crores
Posted On : 2022-11-18 15:46:02( TIMEZONE : IST )
Vivimed Labs Limited has reported Standalone financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 44.3742 crores during the period ended September 30, 2022 as compared to Rs. 50.1873 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. -22.0305 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. -22.2039 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. -2.58 for the period ended September 30, 2022 as compared to Rs. -2.60 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 44.3742 crs | ₹50.1873 crs |  -11.58% |
| Net Profit | ₹-22.0305 crs | ₹-22.2039 crs |  0.78% |
| EPS | ₹-2.58 | ₹-2.60 | 0.77% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 44.3742 crores during the period ended September 30, 2022 as compared to Rs.54.5179 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.-22.0305 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.-23.2992 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.-2.58 for the period ended September 30, 2022 as compared to Rs.-2.73 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 44.3742 crs | ₹54.5179 crs | -18.61% |
| Net Profit | ₹-22.0305 crs | ₹-23.2992 crs | 5.45% |
| EPS | ₹-2.58 | ₹-2.73 | 5.49% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.94.5616 crores during the 6 Months period ended September 30, 2022 as compared to Rs.120.6928 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.-44.2343 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.-25.6346 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.-5.18 for the 6 Months period ended September 30, 2022 as compared to Rs.-3 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹94.5616 crs | ₹120.6928 crs | -21.65% |
| Net Profit | ₹-44.2343 crs | ₹-25.6346 crs |  72.56% |
| EPS | ₹-5.18 | ₹-3 | 72.67% |
Shares of Vivimed Labs Limited was last trading in BSE at Rs. 9.32 as compared to the previous close of Rs. 9.44. The total number of shares traded during the day was 18336 in over 90 trades.
The stock hit an intraday high of Rs. 9.77 and intraday low of 9.11. The net turnover during the day was Rs. 170667.00.
